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Purpose: To determine the type and incidence of predominant microorganisms in certain non-sterile 
pharmaceuticals immediately after collection and one year later. 
Methods: All pharmaceutical samples were subjected to the following examinations: total bacterial 
count and presence of microbial pathogens, using conventional techniques. Attempts were also made to 
identify the isolates. The bioburden rate of some of the syrups and oral drops after storage for 0, 6 and 
12 months were evaluated in order to assess the effect of storage on microbial contamination level. 
Results: Microbial load varied among the pharmaceutical preparations with the highest microbial load in 
suspensions and the lowest in tablets. Bacterial counts ranged from 10 to more than 10
3
 CFU per ml or 
g. The bacterial count at 6 and 12 months were significantly different from that at 0 month (p < 0.05). 
The isolated organisms were either of human flora types, essentially Gram-positive bacteria, or air-
borne fungi. 
Conclusion: The isolated organisms were either of human flora types, principally, Gram-positive 
bacteria, or air-borne fungi and the stored preparations lack an effective preservation. Several 
measures, including equipment automation, monitoring programs and post-marketing surveillanceare 
required to reduce the level of microbial contamination of non-sterile pharmaceutical products. 
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INTRODUCTION 
 
The use of contaminated pharmaceutical 
preparations has proved hazardous to the 
health of the users. There have been reports 
of drug-borne human infections worldwide 
[1]. Contamination of pharmaceuticals with 
microorganisms can also bring about 
changes in their physical characteristics, 
including breaking of emulsions, thinning of 
creams, fermentation of syrups, appearance 
of turbidity or deposit, and changes in odor 
and color [2].  
 
The incidence of microflora in non-sterile 
preparations generally is influenced by the 
nature of the ingredients (whether natural or 
synthetic), the quality of the vehicle and the 
care and attitude of personnel involved in 
their handling [3]. An antimicrobial 
(preservative) may be included in a 
formulation to minimize the risk of spoilage 
and preferably to kill low levels of 
contaminants introduced during storage or 
repeated use of multi-dose preparations, but 
should never be added to mask poor 
manufacturing processes [4]. 
 
Due to the increasing number of immuno-
compromised patients, increased attention is 
paid to the identification and quantitation of 
microorganisms in oral pharmaceutical 
products. Therefore, a systematic approach 
is required by manufacturers of non-sterile 
oral pharmaceuticals to evaluate the 
significance of microbial isolates other than 
primary pathogens and/or those in product 
monographs taking into account the number 
of organisms present, the type of dosage 
form, and the potential hazard to the user. 
Limits for objectionable microorganisms in 
oral products intended for use by immuno-
compromised patient populations, such as 
children and cancer sufferers, should be 
more stringent than the limits for oral 
products intended for treating patients with 
diseases or conditions that do not affect the 
immune system because patients with 
deficient immune systems are more at risk of 
microbial infections. Smaller numbers of 
opportunistic pathogens become infectious 
when resistance mechanisms are impaired, 
either by severe underlying disease, or by 
use of immunosuppressive drugs [5]. 
 
Microbial contamination of non-sterile 
pharmaceuticals may be controlled by (a) 
enforcement and upgrading of GMP rules; (b) 
manipulating physicochemical factors that 
affect the fate of contaminants; and (c) 
incorporating a preservative in the 
pharmaceutical formulation not for the 
purpose of masking bad manufacturing 
practice but to ensure that the product 
remains satisfactory [6]. The objective of this 
study was to evaluate the type and incidence 
of microbial contamination of some oral 







A total number of 300 non-sterile 
pharmaceutical samples were tested. The 
samples comprised of 120 syrups, 20 
suspensions, 60 oral drops, 80 tablets and 20 
nasal drops, and included locally 
manufactured and imported products. 
Samples were randomly purchased from 20 
private community pharmacies in Egypt. The 
average number of samples per pharmacy 
was approximately 15. Some were imported 
and others were manufactured). In addition, 
30 of the preparations (15 each of oral drops 
and syrups) were tested for storage effect on 
the level of contamination. 
 
The media used for the microbiological 
analysis include: casein soya bean digest 
agar, nutrient broth, nutrient agar, 
MacConkey agar, mannitol salt agar, blood 
agar, thioglycollate medium and Sabouraud 
dextrose agar. They were manufactured by 
either Oxoid (Cambridge, UK), Difco (USA) or 
Britannia (Buenos Aires, Argentina). The 
media were prepared according to the 
manufacturers’ instructions. 
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Test sample preparation 
 
For tablets, five units were dispersed in 10 ml 
of sterile normal saline. The dispersion was 
mixed in a vortex mixer for 5 min to dislodge 
possible microbial cells. The solid particles 
were allowed to sediment and the 
supernatant was used for microbial test [7]. 
 
For liquid samples (syrups, suspensions, oral 
and nasal drops), 10 ml of the product 
examined was diluted in sterile buffered 
solution with the following composition: 
peptone  (1.0 g/L), potassium dihydrogen 
phosphate (3.7 g/L) , disodium hydrogen 
phosphate (7.2 g/L), and sodium chloride (4.3 
g/L) . Generally, ten-fold dilutions were 
prepared as described in British 
Pharmacopoeia [8]. 
 
Total viable aerobic bacterial count  
 
Viable aerobic mesophilic bacterial count was 
evaluated using pour plate method [8].  In 
this method, 1 ml of the sample was added to 
20 ml of the liquefied casein soya bean 
digest agar at about 45 
0
C in a Petri dish. At 
least 2 Petri dish for each level of dilution 
were used. The plates were incubated at 30 
– 35 
0
C for 5 days, unless a reliable count 
was obtained in a shorter time. Suitable 
dilutions yielding < 300 colonies were 
counted. The arithmetic mean of the counts 
was taken and number of colony forming 
units per gram or milliliter (cfu/g or mL) was 
calculated. 
 
Detection, isolation and identification of 
potential aerobic bacteria: 
 
An aliquot (1 ml) of the supernatant (for 
tablets) or 1 ml of each liquid dosage product 
was spread on nutrient agar, blood agar, 
MacConkey agar and mannitol salt agar 
plates. All plates were incubated at 37 
0
C for 
24 h. The colonies produced were examined 
morphologically, microscopically and 
biochemically. Morphological identification 
was based on size, diameter, elevation, 
translucency, color, etc of the colonies 
formed while microscopical identification was 
achieved by spreading the bacteria on a 
microscope slide and examined under a 
microscope after Gram staining to identify 
Gram- and –negative bacteria. For 
biochemical identification, a number of 
biochemical tests including carbohydrate 
utilization, catalase production, oxidase 
production, tests, methyl red, Voges-
Proskauer, nitrate reduction, starch 
hydrolysis, tryptophan hydrolysis, hydrogen 
sulfide production, and citrate utilization were 
carried out. 
 
Detection, isolation and identification of 
Clostridium species 
 
Five grams (for tablets) or 5 ml (for liquids) of 
each of the samples sample were mixed with 
50 ml of thioglycollate medium, heated at 80 
0
C for one minute, and then incubated at 37 
0
C for 48 h in a carbon dioxide incubator 
(model Nu-4500/E, NuAire Inc, USA). The 
resulting growth (if any) was sub-cultured on 
the surface of reinforced clostridial agar 
medium plates. 
 
Detection, isolation and identification of 
fungi 
 
One milliliter of the test supernatant (for 
tablets) or of the test liquid product was 
spread on Sabouraud agar plates. The 
plates were incubated at 25 – 27 °C for 72 – 
96 h and fungal growth were examined both 
macroscopically and microscopically.  
 
Effect of storage on microbial load 
 
Microbial contamination of 30 of the sample 
preparations (15 syrups and oral drops each) 
were evaluated for microbial contamination 
(as described above) over a storage period of 
one year at room temperature. Samples were 
withdrawn from the products at 0, 6 and 12 
months, and their total aerobic bacterial 
count and identification of contaminants were 
made. 
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Statistical analysis 
 
In order to assess the statistical difference 
between bacterial counts for the storage test, 
Spearman test for correlation coefficient was 
carried out using SPSS software (version 





Microbial contents of non-sterile 
preparations 
 
All the samples tested were free from 
anaerobic bacteria, coliforms and 
Pseudomonas aeurginosa. Bacterial counts 
in the samples, shown in Table 1, indicate 
that only syrups and suspensions had counts 
greater than 1000 CFU/ml. The other dosage 
forms did not show counts in this range.  
 
Table 2 shows the microbial species isolated 
from the non-sterile pharmaceutical products. 
Again, syrups and suspensions, and also oral 
drops, showed the highest number of 
microbial isolates while tablets and nasal 
drops showed the lowest. 
 
Effect of storage on microbial load  
 
All the preparations showed growth after 
storage except one oral drop product. The 
bacterial count of the products increased 
after storage for 6 and 12 months, 
respectively. For most of the preparations, 
the number of isolated contaminants 
increased with duration of storage. It was 
observed that preparations with high nutritive 
  
Table 1: Total bacterial count (CFU/ml or g) in the different dosage forms 
 
< 100 
CFU/ml or g 
100 - 1000 
CFU/ml or g 
> 1000 
CFU/ml or g 
Dosage form 
(quantity) 
n % n % n % 
Syrup (120)              42 35.0 14 11.7 7 5.9 
Suspension  (20)     3 15.0 5 25.0 2 10.0 
Oral drops  (60) 20 33.3 5 8.3 0 0 
Tablet (80) 4 20.0 2 10.0 0 0 
Nasal drops (20) 15 18.8 1 1.3 0 0 
 
Table 2: Microorganisms isolated from different non-sterile dosage forms 
 
Syrup Suspension Oral drop  Nasal drop  Tablet 
Microbial species 
no. % no. % no. % no. % no. % 
Staphylococcus 
epidermidis 
33 27.5 7 35 13 21.7 3 15 8 10.0 
Staphylococcus 
aureus 
31 25.8 1 5 10 16.7 2 10 5 6.3 
Bacillus subtilis 10 8.3 1 10 6 10.0 1 5 3 3.6 
Aspergillus niger 48 40.0 6 35 20 33.3 4 20 11 13.6 
Aspergillus 
fumigatus 
20 16.7 3 15 11 18.3 1 5 7 8.6 
Aspergillus flavus 16 13.3 3 15 5 8.3 0 0 3 3.5 
Penicillium sp. 11 9.2 0 0 3 5.0 1 5 4 5.0 
Rhizopus 7 5.8 0 0 2 3.3 0 0 0 0 
Cladosporium 3 2.5 0 0 1 1.7 0 0 0 0 
Alternaria 6 5.0 1 5 0 0 0 0 0 0 
 
Note: No. and % represent the number and percent of samples of the dosage form contaminated with the 
microbe 
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ingredients (oral drops and syrups) showed 
not only the highest increase in bacterial 
count and also produced fungal species 
during the storage period. 
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DISCUSSION 
 
The number of isolated microorganisms in 
this study is smaller than that reported earlier 
by other authors [9]. This may be to the 
introduction of better adherence to ‘Good 
Manufacturing Practices’ by pharmaceutical 
manufacturers in recent years. Some of the 
preparations were contaminated by 
Staphylococcus species, suggesting 
contamination from the equipment and/or raw 
material, or poor hygiene of the factory hands 
during production [10]. 
 
The proportion of the products containing 
viable aerobic microbial count (> 1000 CFU 
per ml or g) was small (5.8 % in syrups and 
10 % in suspensions) which indicates that the 
microbiological quality of the examined 
products was, in general, adequate and, in 
most cases, excellent. On the other hand, the 
presence of some molds reflects the storage 
quality of the preparations. The presence of 
certain molds is harmful since they produce 
metabolites that may be toxic to consumers 
[10] and cause rapid deterioration of the 
product due to the biodegradation of the 
different components of formulations arising 
from the production of toxins, such as 
Aspergillus flavus and A. parasiticus [11]. 
In a related work, Okunlola et al. [12] 
investigated the microbial characteristics of 
21 different herbal medicinal products of 
various dosage forms which were sourced 
from some traditional medicine sales outlets 
as well as retail pharmacy outlets in 
southwestern Nigeria. The aerobic bacterial 
count of the products ranged from 5.0 x 10
2
 
to 2.2 x 10
4
 but their microbial load varied 
considerably. Ten (47.6 %) of the samples 
were contaminated by E. coli, 7 (33 % by 
Salmonella, 15 (71.4 %) by Staphylococcus 
aureus and 12 (57.1 %) by fungi. The values 
are considerably higher than those found in 
the present study, probably due to the fact 
that in contrast to our study, natural 
ingredients, which are likely to be more 
contaminated, were mainly used. 
  
The presence of Staphylococcus aureus in 
the oral preparations may not necessarily 
constitute a potential hazard to users since 
not all strains of S. aureus produce the 
enterotoxin that causes poisoning and, in any 
case, the organism would have to grow to a 
density of several million cells/g for its toxin to 
constitute a problem [13]. B. subtilis has 
occasionally been implicated as a causative 
agent of food-poisoning. The infective doses, 





 CFU/g, which is far higher than the 
concentration of endospore-forming isolates 
found in any of the oral pharmaceuticals 
examined in this study [14]. 
 
In the present study, contamination rate was 
lower in tablets than the other dosage forms. 
This may be attributed to the lower water 
activity of tablets which is usually < 0.60) [15]. 
Physical preservation of syrups is facilitated 
by reduced water activity arising due to the 
addition of sugar [4]. Low water activity 
values normally inhibit the growth of bacteria 
such as members of the family, 
Enterobacteriaceae, as well as aerobic and 
anaerobic spore formers, but allow the 
growth of certain vegetative microorganisms, 
such as staphylococci and micrococci, 
especially S. aureus which grow below a 
water activity of 0.86 [6] . Hence 
Staphylyloccoci species survived and grew 
during the period of storage in this study. 
 
Preservative effectiveness might have been 
modulated by changes in microbial cell 
envelope and glycocalyx; furthermore, the 
presence of slime layer under conditions of 
limited nutrition may promote 
microclonization and formation of biofilm with 
significant resistance to antimicrobial agents 
[16]. Also, preservative availability may be 
reduced by interaction with packaging 
material, (e.g., quaternary ammonium 
preservative levels are reduced by adsorption 
on plastic or glass containers) or by 
volatilization during opening and closing of 
containers; hence, preserved medicines 
should be packed in sealed, impervious 
containers during storage [4]. 
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CONCLUSION 
 
The isolated organisms were either of human 
flora types, essentially Gram-positive 
bacteria, or air-borne fungi. Furthermore, the 
stored preparations lacked effective 
preservation. Using production systems in 
which personnel are removed from critical 
zones, e.g., equipment automation, should 
improve the microbial quality of 
pharmaceuticals. Microbial monitoring 
programs are necessary to estimate the 
bioburden of the environment. Post-
marketing surveillance should be put in place 
to detect any problem concerned with product 
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